BI 894999 First in Human Dose Finding Study in Advanced Malignancies
Ontology highlight
ABSTRACT: This study is open to adults with different types of advanced cancer (solid tumours). The study is also open to patients with diffuse large B-cell lymphoma in whom previous treatment was not successful. In some countries, adolescents who are at least 15 years old and who are diagnosed with NUT carcinoma can also participate. No standard treatment exists for this rare and aggressive form of cancer.
The purpose of this study is to find out the highest dose of BI 894999 that people can tolerate.
BI 894999 is tested for the first time in humans. Participants take tablets once daily. The study also tests whether participants can tolerate BI 894999 better when taken continuously or with breaks in between.
Participants can stay in the study as long as they benefit from the treatment and can tolerate it.
The doctors also regularly check the general health of the participants.
DISEASE(S): Diffuse Large B-cell Lymphoma Nos,Carcinoma,Nut Carcinoma,Nut Midline Carcinoma,Small Cell Lung Cancer,Advanced, Unresectable And/or Metastatic Solid Tumours, Which Have Failed With Conventional Treatment Or For Which No Therapy Of Proven Efficacy Exists, Or In Patients Who Are Not Amenable To Standard Therapies And Patients With Diffuse Large B-cell Lymphoma (dlbcl) For Whom There Are Limited Or No Standard Treatment Options Available,Castration-resistant Prostate Cancer,Colorectal Cancer Nos,Malignant Solid Tumour,Neoplasms
PROVIDER: 2195564 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA